Biotek-snakken — Maj 2026
-
-
Regnskab fra Arvinas 5 maj så vidt jeg husker, så må vi se hvad de siger om partneraftale forhandlingerne. De har hele tiden sagt at de skred godt fremad, men nu kom godkendelsen en god måned før tid, så håber de lukker aftalen meget snart. Ellers må Pfizer i sving!
-
FDA godkender Pfizers og Arvinas’ brystkræftmiddel trods svage forsøgsdata
Pfizers milliardaftale, skuffende fase 3-resultater og fyringer hos Arvinas danner bagtæppe for godkendelsen af Veppanu.
(medwatch.dk)
-
Pfizer, Arvinas join SERD club with Veppanu approval
Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.
pharmaphorum (pharmaphorum.com)
-
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, May 12, 2026 at 8:00 a.m. ET. The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be ava
Yahoo Finance (finance.yahoo.com)
-
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that it has entered into an exclusive, global license agreement with Arvinas, Inc. (Arvinas) and Pfizer Inc. (Pfizer), subject to regulatory clearance, to develop, manufacture and commercialize VEPPANU™ (vepdegestrant), the first and only U.S. Food and Drug Administration (FDA)-approved oral PROteolysis TArgeting Chimera (PROTAC). PROTACs are part of a
Yahoo Finance (finance.yahoo.com)
-
Sukkeralf, der var da ikke noget i deres CC som skulle kunne få den ned med 10+%. udsættelse af IND til næste år med en god forklaring tror jeg ikke var årsagen.Tænker der er komme lidt flere retail investorer i den pga af de fine stigninger som solgte ud pga det på papiret dårlige regnskab. bum bum
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind